The deal, signed in the third quarter of 2011, is the largest of its kind globally to date. AOK plans to use SAP HANA to conduct real-time analyses of mass medical data in order to determine patterns of disease in its often regional variants in early stages and offer individualized pre-emptive programs. In doing so, the company aims to be more appealing to its customers and even more efficient even dysfunction . Like each of Germany’s statutory medical health insurance funds, AOK must cope with a huge and constantly growing ocean of data: 12 independent regional health insurance money with 24 million insurants, over 370 million outpatient treatment instances, 1. In Germany’s liberalized healthcare marketplace, approximately 150 statutory health insurance money wrangle for the interest of customers.
Â Â Â Â.. A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV A.P. Pharma, Inc. , a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for its lead product candidate, APF530, for the prevention of acute – and delayed-onset chemotherapy-induced nausea and vomiting . A.P. Pharma expects confirmation of acceptance from the FDA and a Prescription Drug User Fee Act goal day within the next few weeks. The ongoing company anticipates a six-month examine by FDA.P. Pharma and brings this important therapeutic option one stage closer to cancer patients suffering from CINV, said John B. Whelan, A.P. Pharma’s president and chief executive officer. Now that we’ve resubmitted the NDA, our focus shall change to pre-marketing and pre-commercialization activities in anticipation of potential FDA authorization of APF530.